#1ResMed Corporate & Investor Presentation Updated: April 28, 2022#2Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com). In addition to historical information, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed's current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, tax outlook, and the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. Forward-looking statements can generally be identified by terminology such as "may", "will”, "should", "expects", "intends", "plans", "anticipates", "believes", "estimates”, “predicts", "potential", or "continue", or variations of these terms, or the negative of these terms or other comparable terminology. ResMed's expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the "Risk Factors" identified in ResMed's quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements. 2 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#3Company Overview & Strategy ResMed#4Who we are / what we do • • • Listed on NYSE & ASX, ~$35B market cap World-leading digital health company with over 17 million 100% cloud-connectable devices - 19+ million patients in AirView monitoring ecosystem - 115+ million patient accounts in out-of-hospital care network Innovative designer and manufacturer of award-winning devices and cloud-based software solutions - Diagnose, treat, and manage sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions Products and solutions designed to improve patient quality of life, reduce impact of chronic disease, and lower healthcare costs Cloud-based software solutions and devices designed to provide connected care, improving patient outcomes and efficiencies for healthcare providers - Tools that allow fewer people to manage more patients - Empower patients to track own health outcomes ResMed myAir Thursday, October 15 95 100 points Excellent results, Luis! As you want to see the benetts in your ide, your cock 000 Coaching tips Managing mouth leak Set tips to solve problems with nouth eas My sleep night Thursday, March 6 85 100 posts Do History Elbrary Hello Luis Garcill (?) 47:34 usage hours 70m Adjust mask sod 19 11 events per hour 3 3 mask onvo 32 Total myAir score 95/100 My equipment Naximizing comfort using humidification Mamize your comfort using humidification Achieve a good mask every ResMed AirFit F10 ResMed AirSense 10 Autoset Change Charge Manage the way you cave ton-Ching settings Coupon That's a great score, John! You're well on your way. Home 2000- MY OPTIONS MY SLEEP VEW ResMed 5:45 usace hours Good mask seal 60/70 MORE 18/20 24 events per hour 3/5 4/5 01 mask onjoft C Tosal myAir score 00 85/100 8 Cosley 4 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 MAX ResMed#5Why invest? - driving long-term shareholder value Growth & Innovation Global leader in digital health for sleep and respiratory care • Long-term growth opportunities. 8,900+ patents and designs ~7-8% of revenue invested in R&D . 0000 Market Dynamics Underpenetrated markets in sleep and COPD Healthcare costs continue to increase · Focus on improving patient outcomes Value-based technology solutions Financial Results Historical revenue and profit growth • Recurring revenue • Operating excellence program Strong track record of disciplined capital deployment Total Shareholder Return (NYSE shares as of 03/31/2022): 1-yr 26% 3-yr 139% 5-yr 255% 5 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#6ResMed 2025 | Patient-centric, digitally-enabled strategy ResMed 2025 250 million lives improved in out-of-hospital healthcare in 2025! Purpose⚫ Empower people to live happier, healthier, and higher quality lives in the comfort of their home Growth Focus Global health epidemics in sleep apnea, COPD, other major chronic conditions, and SaaS solutions that improve care in out-of-hospital settings Growth Advantage Transform care through innovative solutions and tech-driven integrated care to drive superior outcomes, experiences, and efficiency Growth Foundations High-performing, diverse, and entrepreneurial people Industry-leading innovation and business excellence Digital health technology and scientific leadership 6 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 N ResMed#7Unlocking markets and expanding access with evidence and advocacy Diverse evidence generating capabilities. Established scientific leader Solid foundation of clinical trials 1,096 # of publications from 1996 onward 484 269 ResMed Peer 1 Peer 2 Strong history of market development and growth Better access and advocacy Unlocking reimbursement U.S. Competitive Bidding Program delay and removal of NIV from the program Supporting the creation of new U.S. physician remote monitoring codes • On-time device reimbursement in key markets Thought leadership • • Achieved leadership positions in key global MedTech associations Thought leader in European and member state health data policy and remote monitoring reimbursement conversations Engagement on key policies Health Technology Assessments (e.g., UK NICE) Analyses of French health insurance data to demonstrate the positive impact of CPAP therapy on lowering mortality rates Economics and outcomes for value- based decisions ResMed Evidence Generation Team Behavior and population health research 1KOLs: Key opinion leaders Real world evidence studies with KOLs1 7 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#8Positioned to win Growing the market through commercial excellence and expanding market access Driving digital innovation in sleep and respiratory care to radically improve patient experience and outcomes Transforming out-of-hospital care at scale to drive better outcomes, lower costs, and improve quality of life 8 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#9Our Business: Sleep & Respiratory Care ResMed#10Proactive care to capture significant underpenetrated markets • Chronic disease is the largest driver of healthcare spending in developed economies Sleep apnea Leading indicator, and a contributing factor, to many chronic illnesses More than 80% undiagnosed Demonstrated positive dose-response relationship between CPAP usage and lower healthcare costs . • • COPD Largely undiagnosed COPD sufferers in high-growth markets such as China, India, Brazil, and E. Europe >100M² Acute treatment costs to healthcare systems are large - Europe: €48B per year4 U.S.: ~$50B per year5 More than 3M people worldwide die each year due to COPD1 Asthma Significant opportunity to improve adherence and improve patient-physician interaction Leveraging Propeller for increased data related to symptom occurrence and acute triggers Opportunity to partner with patients, providers, pharmaceutical companies, and payors to drive improved quality of life 936M sleep apnea patients Total addressable market 380M COPD patients 2,3 330M asthma patients6 Well-positioned to expand proactive treatment of chronic diseases 1World Health Organization. The top 10 causes of death: Fact sheet: No310 (2014, May) accessed 20Jul16 2 https://www.ncbi.nlm.nih.gov/pubmed/26755942 3 Company estimates based on World Health Organization estimates and Zhong et al. "Prevalence of Chronic Obstructive Pulmonary Disease in China" Respiratory and Critical Care 4 European Respiratory Society, European Lung White Book http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/accessed 20 Jul16 5 Guarascio et al. Dove Med Press, 2013 Jun 17 6 The Global Asthma Report 2018. http://globalasthmareport.org/burden/burden.php. Accessed April 26, 2022. 10 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#11Driving digital innovation across Sleep and Respiratory Care Well-positioned to drive digital innovation with... Market-leading connected therapies and unique suite of software solutions ^ ^ ^ Leveraging our device and software capabilities to increase patient engagement and success with therapy Driving greater provider efficiency and effectiveness to increase patient adherence and lower labor intensity Uniquely positioned to deliver value through our software solutions given access to rich and proprietary data from our connected devices Where we are going Building on our established leadership position to drive more streamlined and integrated experiences through digitally powered integrated care models Leveraging our leadership position to transform Sleep and Respiratory Care 11 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#12Transforming care by enabling an integrated healthcare model Customer(s) Patients Payers Sleep apnea patient journey Integrated patient journey Identification Diagnosis Treatment set-up Healthcare providers Patients Payers Short-term adherence Resupply Long-term adherence Disease management Billing & Collecting Services + 000 Treatment Data Software Machine learning & analytics Benefits Reach and engage untreated patients Enable seamless patient experience Provide better care coordination Drive greater customer preference for ResMed solutions and brand Enable new care models Driving digital innovation across all aspects of the patient journey 12 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#13Growing the market through new channels and partnerships New channel Joint venture . . ResMed × ♥CVSHealth® Work closely with CVS to create streamlined sleep apnea patient journey in Health HUB locations where patients can be screened, assessed, and setup on therapy as well as purchase related products all within the CVS ecosystem Educate CVS pharmacy colleagues, care concierge, and center of excellence team members; provide input into digital efforts to effectively identify presence of sleep apnea and provide recommendations for further testing as necessary . . ResMed X verily = PRIMASUN Develop software solutions to identify, engage, and enroll individuals suffering from sleep apnea and other sleep- related disorders - guide them to get diagnosed and successfully treated Participate in the ecosystem of Verily companies to access sleep apnea patients and help them get diagnosed and treated • Generate further evidence of the positive impact of sleep apnea treatment on other chronic health conditions Expanding our ability to reach and serve patients 13 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#14Nasal Full Face Leadership in OSA treatment with physical devices Latest launch Resid AirSense™ 11 MoMed 虎 Devices AirMini™ 90 RosMed AirSense™ 10 AirCurve™ 10 Key differentiators Quietest, most intuitive devices on the market AirSense 11: newest, most connected device Expanding digital tools for patient experience, including patient engagement built into device • Minimalist Masks1 Freedom Universal Fit Ultra Soft AirFit™ F30 AirFit™ F30i AirTouch™ F20 AirFit™ F20 AirFit™ P10 AirFit™ N30 AirFit™ N30i AirFit™ P30i AirTouch™ N20 AirFit™ N20 1Curent in-line masks being promoted; not an exhaustive list 14 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ✓ Premium comfort and machine-agnostic masks; widest range of masks on the market meeting the broadest set of patient needs Largest database of facial features; focused on designing for fit Expertise and experience in translating clinical knowledge into product features (e.g., comfort, durability) ResMed#15Data-driven sleep apnea therapy • AirSense 11 is a two-way communication data platform - - - Both cell and Bluetooth connectivity Seamless pairing with myAir app and directly to the cloud Very rich consumer-like experience on myAir app Patient questions and prompts on the device Built for Over-the-Air (OTA) upgrades Add new features without new hardware Improved patient adherence - - ~60% uptake of myAir patient engagement app vs ~25% on AS10 Up to 87% adherence with use of myAir, AirView, AirSense platform Even more streamlined provider workflows and lower costs Improved patient management Home MY OPTIONS - Future: Patient Reported Outcomes Metrics (PROMs) for payors and health systems + MORE S AirSense™ 11 MY SLEEP VIEW ResMed MAX AirSense 11 is the device platform that will enable us to deploy AI/ML into sleep therapy 152022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#16Leadership in OSA treatment with data applications ResMed прот myAir™ 91 Aisalaan int and anemid Resived 1 0 пожелат Til RAH CO о ResMed AirView™ ResMed ResMed 2014. Alter Eugene, Judy ResMed New Patients Training for HME Training for Sleep Lab Main Menu Home User-friendly, intuitive platform provides milestone accomplishments and motivation to patients, increasing therapy adherence, and improving sleep quality Focused on app enhancements to enable long-term adherence for life vs. short-term (e.g., app-based nudges) Clear-cut market leader with over 4M U.S. patients registered to the myAir platform across the website and app Recently launched upgraded version: myAir 2.0 Key differentiators Large installed base with over 19M patient enrolled in our cloud-based software solution Seamless integration with ResMed devices enhances provider efficiency and improves patient monitoring through industry-leading remote diagnostic tools Increased data capture enables us to drive more personalized care to improve the patient experience Unlocking value for both patients and providers 16 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#17At the forefront of Respiratory Care Patient Management Pesed Aw Ventration patients wwwww Pace: Jimmy AirView" for Ventilation Bilevel Ventilation Digital Therapeutics Duty code Propeller Non-invasive Ventilation (NIV) Jessed ˇˋ High-Flow Therapy Realled Highlights Widest range of therapies for higher acuity respiratory patients, including COPD and asthma HFT Broadest set of digitally connected respiratory therapy devices AcuCare HFNC Lumis™ High flow nasal cannula Life Support Ventilation AirCurve™ 10 Lumis™ 100 Stellar™ 100 Astral™ Astral™ 150 Life support ventilator VPAP ST Market leading platform for managing inhaled medications Premier solution for remote management of ventilated patients Patient Acuity The right device, for the right patient, at the right time 17 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#18Leveraging our scale with data and digital solutions Now Next With more than 11.5 billion nights of therapy usage data we have a unique ability to create actionable insights: For Patients • Coaching and usage help in context through myAir app For Providers • Patient management by exception, streamlined workflows, lower costs, higher adherence, and increased revenue For Payors • Increased patient adherence and improved ROI on therapy For Patients Personalized coaching in myAir based on Machine Learning For Providers Patient management by prediction For Payors • Proof that it pays to find and treat sleep apnea patients; improved patient management with PROMS Benefitting all stakeholders with better outcomes and lower costs 18 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#19Our Business: Software as a Service (SaaS) ResMed#20Leading provider of cloud-based software for out-of-hospital care providers across multiple settings Our breadth uniquely positions us to be the innovation engine for providers Out-of-hospital care ecosystem Software solutions and data 20 Home Medical Equipment Providers brightree by ResMed 000 MatrixCare® by ResMed Pharmacy/ Infusion Home Health Hospice/ Palliative Care Private Duty Skilled Nursing Senior Living We are the gateway to out-of-hospital care © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 Life Plan Communities ResMed#21We have a leading position across these markets PATIENT & RESIDENT RECORDS API CALLS & OTHER TRANSACTIONS USERS 115M+ 10M+ 700K+ IN OUR OUT-OF-HOSPITAL CARE NETWORK PER DAY Continuously expanding market potential $2.0B FY 2021 estimated market size ✓ HME: #1 position and expanding into Pharmacy / Home Infusion ✓ Home Health & Hospice - Large: 2020, 2021, 2022 Best in KLAS Award ✓ Skilled Nursing Facility: Multi-year winner of Best in KLAS Award $393M LTM 3Q22 ResMed SaaS revenue - One of the leading market positions across the markets we serve – with room to grow 21 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#22Uniquely positioned to address provider needs brightree by ResMed MatrixCare by ResMed Demand for greater coordination across provider markets 000 0 0 0 Home Medical Equipment Providers Pharmacy/Infusion Home Health Hospice/ Palliative Care Private Duty Skilled Nursing Senior Living Life Plan Communities Providers are diversifying and lines are blurring across the continuum; Skilled nursing facility owners are moving into home-based care We are working with our customers to address their needs, holistically across the markets they serve • Our solutions are supported by the richness of our data Differentiated value creation within SaaS portfolio through breadth and commitment to innovation 22 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#23Digital Health Technology ResMed#24Our digital health solutions improve outcomes and lower costs ResMed ecosystem Connected devices and digital health Propeller AirView™ APPS/DIGITAL THERAPEUTICS PATIENT/ CONSUMER DEVICES CLINICIAN H myAir™ IDN Out-of-hospital platform brightree by ResMed >> Artificial intelligence MatrixCare Machine learning by ResMed HME/PAYORS HEALTHCARE first by ResMed >> Focused on interoperability so our ecosystem works with the broader healthcare ecosystem 24 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 Patient outcomes Business outcomes Operations ResMed#25We transform 11.5+ billion nights of medical data into useful outcomes End-to-end digital health solutions in sleep, respiratory care, and out-of-hospital healthcare ApneaLink Air Type ill home sleep testing device ResMed ApneaLink Air DIAGNOSIS Air10™ series AirView™ AirView™ ActionGroups MyAir 12 34 Cor: b 01011 Ongping alu 05 THERAPY AirView™ DIAGNOSTICS Astral™ with RCM AirMini™ ResMed 25 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 90 10 78 Hatake red 11 B 10 brightree. MONITORING & MGMT. PATIENT ENGAGEMENT BILLING & INTEGRATIONS Go Scripts ReSupply Propeller Compte Reina Dumas ResMed Data Exchange 3rd Party Integrations I ResMed#26Global leader in digital health 19+ million patients on AirView™ 2+ million diagnostic tests processed in the cloud ~100 API calls per second from integrators 26 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 85 ब >17 million 100% cloud connectable devices worldwide >115 million accounts in out-of-hospital care network 4+ million patients have signed up for myAir™ ResMed#27Recent Quarterly Results ResMed#28Q3 FY22 financial results $ in millions, except per share amounts Revenue Non-GAAP gross margin* Non-GAAP operating income* Non-GAAP EPS* 3Q22 $864.5 +12%, +14% CC 58.1% (150) bps $253.0 +5% $1.32 +2% * Refer to Non-GAAP reconciliations in the Appendix. 28 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 Diversified revenue by business & by geography OOH SaaS 12% Masks & Other 38% Revenue by business 3Q22 Devices 50% OOH SaaS 12% Europe, Asia, and Other 33% Revenue by region 3Q22 U.S., Canada, and Latin America 55% ResMed#29Capital allocation $ in millions 3Q22 Higher priority . Reinvest in product development for Cash and cash equivalents $202 Reinvest for growth high-return organic growth 7-8% of revenue invested in R&D Debt $681 Net debt $479 Pursue M&A Free cash flow $69 Actively evaluate potential acquisitions Pursue targets aligned with long-term strategic goals and financial objectives Unused borrowing capacity $1,570 NOTE: Values may not calculate due to rounding Support dividends Regular return of cash to shareholders through dividend at a level that is meaningful and sustained During 3Q22 $67M invested in R&D (8% of revenue) Paid $61M in dividends to shareholders Lower priority 29 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 Opportunistically • repurchase shares Current program suspended following Opportunistic repurchase of shares acquisitions of MatrixCare and Propeller ResMed#30Track record of strong financial returns for shareholders (Financial data as of March 31, 2022) $2.0 Revenue ($B) 12% CAGR $3.5 LTM 3Q17 LTM 3Q22 Non-GAAP Operating Income ($M) $504 16% CAGR $1,062 LTM 3Q17 LTM 3Q22 Non-GAAP EPS $2.80 15% CAGR $5.65 LTM 3Q17 LTM 3Q22 Total shareholder return, TSR (NYSE shares as of 03/31/2022): 1-yr 26% | 3-yr 139% NOTE: See reconciliation to GAAP in Appendix | 5-yr 255% 30 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#31Our vision is to empower people to take control of their health so they can sleep better, breathe better, and live better lives outside the hospital Connected therapy devices Connected medications Masks Software solutions 95 + Improve the patient experience + Increase long- + Lower the + term adherence cost of delivery Improve health + Measurably + improve Improve QOL outcomes economic outcomes outcomes Services (Resmed 360) Our business aim is to make our device therapies and connected systems indispensable by combining them with intelligent data products#32In the last 12 months, we changed over 137 million lives with our digital health products and cloud-based software solutions MAT&T WC-F9 10:23 PM my sleep night Wednesday, January 31- myAir score 85 100 points That's a great score! You're well on your way to improving your health 5:58 usage hours 60/70> Adjust mask seal 5.4 events per hour o 3 mask onoff 415> DHANA Our aspiration is to improve 250 million lives in 2025#33Contact Investor Relations Phone: (858) 836-5971 Email: [email protected] Website: investor.resmed.com#34APPENDIX ResMed#35Reconciliation of non-GAAP financial measures The measures "non-GAAP gross profit" and "non-GAAP gross margin" excludes amortization expense from acquired intangibles related to cost of sales and are reconciled below: (Unaudited; $ in thousands, except for per share amounts) Revenue GAAP Cost of sales Less: Amortization of acquired intangibles Less: Restructuring-cost of sales (A) Non-GAAP cost of sales GAAP gross profit GAAP gross margin Non-GAAP gross profit Non-GAAP gross margin Three Months Ended March 31, 2022 March 31, 2021 2022 Nine Months Ended March 31, March 31, 2021 $ 864,500 $ $ 373,303 $ (A) (10,982) 768,767 $ 2,663,390 $ 2,320,722 321,509 $ 1,161,585 $ 972,319 (10,924) (33,271) (34,066) (5,232) $ SA 362,321 $ 310,585 $ 1,128,314 $ 933,021 $ SA $ 491,197 $ 56.8% 502,179 $ 58.1% 447,258 $ 58.2% 458,182 $ 59.6% 1,501,805 56.4% 1,535,076 57.6% $ 1,348,403 58.1% $ 1,387,701 59.8% Note regarding non-GAAP reconciliations ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions, restructuring expenses and the (gain) loss on equity investments from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. 352022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#36Reconciliation of non-GAAP financial measures, cont'd The measure "non-GAAP income from operations" is reconciled with GAAP income from operations below: (Unaudited; $ in thousands, except for per share amounts) Three Months Ended March 31, 2022 March 31, 2021 Nine Months Ended March 31, 2022 March 31, 2021 $ 234,265 $ 223,426 $ 744,889 $ 662,040 10,982 10,924 33,271 34,066 7,730 7,445 23,175 23,377 5,232 8,673 SA 252,977 $ 241,795 $ 801,335 SA $ 733,388 GAAP income from operations Amortization of acquired intangibles-cost of sales (A) Amortization of acquired intangibles-operating expenses (A) Restructuring cost of sales (A) Restructuring operating expenses Non-GAAP income from operations (A) $ Note regarding non-GAAP reconciliations ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions, restructuring expenses and the (gain) loss on equity investments from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. 36 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#37Reconciliation of non-GAAP financial measures, cont'd The measure "non-GAAP net income" and "non-GAAP diluted earnings per share" are reconciled with GAAP net income and GAAP diluted earnings per share in the table below: (Unaudited; $ in thousands, except for per share amounts) Three Months Ended March 31, 2022 March 31, 2021 Nine Months Ended March 31, 2022 March 31, 2021 GAAP net income (loss) $ 179,012 $ Amortization of acquired intangibles-cost of sales, net of tax (A) 8,374 (78,481) $ 8,395 584,376 $ 279,405 25,373 26,136 Amortization of acquired intangibles-operating expenses, net of tax (A) 5,894 5,721 17,673 17,936 Reserve for disputed tax position (A) 254,776 4,111 254,776 Restructuring cost of sales, net of tax (A) 4,663 Restructuring operating expenses, net of tax (A) 7,730 (Gain) loss on equity investments (A) (8,476) Non-GAAP net income (A) $ 193,280 $ GAAP diluted shares outstanding 146,962 Anti-dilutive shares excluded from GAAP Non-GAAP diluted shares outstanding 146,962 GAAP diluted earnings (loss) per share Non-GAAP diluted earnings per share (A) $ SS 1.22 $ $ 1.32 $ 190,411 $ 145,513 858 146,371 (0.54) $ 1.30 $ 631,533 $ 582,170 147,034 146,394 147,034 146,394 4.30 3.97 $ $ 1.91 3.98 Note regarding non-GAAP reconciliations ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions, restructuring expenses and the (gain) loss on equity investments from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. 37 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#38Striving for excellence in environmental, social, and governance processes Eliminating unnecessary waste We work to eliminate unnecessary waste in all our systems & processes, such as minimizing our use of natural resources. Minimizing pollution Product stewardship We are minimizing pollution, in particular our non-biodegradable waste to landfill. We design and develop products with reduced impact on the environment through their lifecycle. Responsible compliance We fulfill all relevant and applicable compliance obligations in the countries and communities that we operate in. Increased awareness and continual improvement We drive internal awareness of environmental impacts and monitor our performance through collaboration with others to make continual improvements Recognized by others for leading in this space: Newsweek's 2022 "America's Most Responsible Companies" WSJ's 2021 "Management Top 250" • 38 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 AMERICA'S MOST 2021 RESPONSIBLE Newsweek COMPANIES statista WSJ MANAGEMENT TOP 250 ResMed#39Turning big data into actionable information Pioneering innovation and providing clinical evidence that support better patient outcomes and improved business efficiencies for customers AirView™ myAir TM 85 85 85 Labor Costs? 159% World's largest study for adherence > 128,000 patients 121% patient adherence with automated compliance coaching 1 New Patient Setups³ Munafo, et al. Sleep Breath 2016 1234 1. Hwang, et al., AJRCCM 2017 2. 3. 4. 39 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 155% Data based on monthly patient setups and compliance rates of DME customers from February 2014 - March 2015. Historical results for this provider over the stated time Malhotra et al CHEST 2018 124% patient adherence with patient engagement4 ResMed#40Improving adherence to therapy with patient monitoring and resupply ResAdhere: remote monitoring + mask resupply drive improved adherence In a study of ~100k patients with AirView cloud-connected devices... Resupply group (AirView + Brightree) Control group (non-resupply) Probability on Therapy (%) 100 100% 90 Time to Drop out (days) + brightree by ResMed AirView™ 84% 66% 360 ...the likelihood of therapy termination decreased by >50% after one year and there was a significant increase in daily PAP usage Benjafield, et al. AJRCCM 2018 (abstract) Note: De-identified data from Brightree and AirView were sent to a third-party independent statistician who provided the anonymized analyses and findings. 40 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#41Long-term CPAP treatment decreases mortality rates and reduces the risk of comorbidities Recent prospective cohort study from the UK published in ERJ Open Research reconfirms treating OSA with CPAP improves health outcomes 30 year study duration 4,502 diagnosed OSA patients 15 year average follow-up time Those who did not use CPAP were 5.63x more likely to die than a long-term (>5 years) CPAP user The study also reconfirms with new data that untreated OSA leads to a greater risk in developing: Dodds et al. ERJ Open Res 2020 41 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 Myocardial Infarction (heart attack) Type 2 Diabetes Mellitus Ischemic Heart Disease ResMed#42Reducing mortality with PAP therapy U.S. multicenter, population-based cohort study . Study included 392 patients with sleep apnea, with 11 years of follow-up • Positive airway pressure therapy associated with a 62% lower risk of all-cause mortality Death rate was twice as high for persons who did not receive positive airway pressure therapy - (24.7 vs 12.8 deaths per 1000 person years, p = 0.03) Lisan Q et al. JAMA Otolaryngol Head Neck Surg 2019 42 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 Proportion Surviving, % 100 90 80 70- 60 0 Sleep Heart Health Study HR, 0.38 (95% CI, 0.18-0.81) PAP prescribed PAP not prescribed 5 10 15 20 Time, y ResMed#43Demonstrated positive dose-response relationship between increased CPAP usage and lower healthcare costs For every one hour per night increase in PAP usage there was an 8% decrease in inpatient visits and a 4% decrease in overall acute care visits.1 8% Each Hour 4% PAP Usage 1. Kirsch DB et al. J Clin Sleep Med 2019 * Overall visits" includes inpatient, ED, and observation visits. 432022 ResMed | Corporate & Investor Presentation - updated 28APR22 Inpatient Overall Visits Visits* ResMed#44Study demonstrates the effectiveness of CPAP therapy and quality of life improvements for those with mild obstructive sleep apnea MERGE trial: clinical effectiveness of CPAP treatment in patients with mild obstructive sleep apnea Demonstrated improvement in 56. ● CPAP -Standard care Quality of Life (SF-36 vitality scale) Treatment effect 7-5 (95% CI 5-3-9-6); p<0-0001 54- for CPAP patients vs. standard care Symptomatic benefits: • Reductions in sleepiness 52 Mean vitality score (95% CI) 46- 48- g Improvements in fatigue and depression Compelling evidence supports the need and benefits of treating mild OSA Combined with recently published global prevalence research, 936M patients worldwide can benefit from PAP treatment 44 42- T 40 Baseline Month 3 Visit Change in SF-36 Vitality Scale in Patients with Mild OSA per AASM 2012 Wimms et al. Lancet Respir Med 2019 44 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 MMERGE Blackpool Liverpool Dundee Cambridge Oxford Taunton Plymouth UK Respiratory Sleep Research Network Newcastle Stevenage London (G&ST) London (RB&HT) ResMed#45Big data analysis drives insights for treatment of central sleep apnea Patients with treatment-emergent central sleep apnea (CSA) are 2x more likely to terminate therapy • Opportunity to rethink conventional therapeutic options Minimize risk of therapy termination through early diagnosis • Regularly monitor patients to support adherence to treatment 100 50 Analysis of ~200k CSA patients 22% increase in adherence CMS adherence on CPAP prior to switching 62.7% CMS adherence after switching to ASV 76.6% Switching from therapy CPAP to ASV improved relative adherence by 22% Patients who switched from CPAP to ASV had fewer apneas and hyponeas during sleep 452022 ResMed | Corporate & Investor Presentation - updated 28APR22 HAH CHEST Journal ResMed#46Patient engagement drives 87% adherence to PAP therapy Cumulative percentage of patients 1.0 0.9 0.8 NO L 0.7 0.6 0.5 0.4 0.3 0.2 0.1 -AirView only (N=85,358) ―myAir (N=42,679) 0.0 0 10 20 30 40 50 60 70 80 90 Days to achieve CMS adherence About the clinical study • . Largest clinical study 1 to date assessing the impact of adding the myAir patient engagement tool for PAP patients already using AirView Resulted in more than 137 million nights of data • Patients in both groups were treated with PAP therapy over the 90 days Personalized engagement benefits everyone • Significantly improves adherence Can be achieved with minimal burden on providers Patients who use myAir and AirView improved adherence by 17% over those who only use AirView 1. Malhotra et al CHEST 2018 46 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#4747 Big data analysis demonstrates CPAP treatment decreases mortality rates by 39% Objective: to investigate the effects of CPAP therapy use on all-cause mortality in patients with OSA . ALASKA study conducted using data from SNDS, one of the largest anonymized claims databases in the world representing over 99% of the French population - Included >176,000 people in France ― New CPAP users aged 18+, initiated treatment Jan'15-Dec' 16 . OSA patients who continued CPAP therapy over the 3-year study period were 39% more likely to survive than those who discontinued CPAP therapy 1. Pepin JL et al. Chest 2022 Survival probability 1.00 0.98 0.96 0.94 CPAP therapy termination CPAP therapy continuation HR 0.61, 95% confidence interval [CI] 0.57-0.65; Log-rank p<0.01 0 0 1 2 3 Time [years] CPAP treatment is a case of life or death © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#48Opportunity to shift care from hospital to home . Healthcare costs are on the rise Combining non-invasive ventilation (NIV) with home oxygen therapy (HOT) Reduces hospitalization and mortality by 51% - - Increases time to hospital readmission or death by ~90 days. Admission-free survival by treatment arm over one year JAMAⓇ The Journal of the American Medical Association Admission-free Survival % 1001 80 40 20 20 Adjusted hazard ratio, 0.49 (0.31-0.77); P=.002 Home Oxygen Plus Home NIV Home Oxygen Alone Combination of HOT with NIV reduced hospital readmissions by 58.3% Combination of therapies provided improved patient quality of life and saved >$50k per quality of life adjusted year 0- 0 2 4 6 8 10 12 Time (months) 1 P. Murphy et al., Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation. A Randomized Clinical Trial, JAMA .Published online May 21, 2017. doi:10.1001/jama.2017.4451. 48 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed#49Propeller Health: Digital health solutions for inhaled COPD and asthma medications Establishes ResMed as a leading provider of COPD and asthma patient management solutions Uses FDA-cleared sensors with inhalers and a consumer app to track medication usage, provide insights to patients, and access to clinical data for physician monitoring • • ResMed now has end-to-end digital health solutions for COPD patients across multiple stages of the disease and continuum of care Enables Propeller to deliver value to patients, caregivers, providers, payers, pharmaceutical companies, and other healthcare organizations Contracts with pharma companies to support clinical trials and biologics LIFE SCIENCES gsk (1) NOVARTIS ORION ($$ Patients + $$ Increased drug adherence and sales Improved clinical trial speed and enhanced time to market 49 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 Health and economic outcomes Direct and value-based contracts with health systems and payers HEALTHCARE Payers Top 50 Payers Propeller PBMs EXPRESS SCRIPTS Clinical insights and efficiencies Health systems Dignity Health. Patient Engagement $$ Patients + $$ Pharmacies Walgreens ResMed#50Propeller has demonstrated compelling clinical outcomes L 1 Impact of the Propeller solution tracking inhaler usage and location SABA use over time # per day Symptom free days % 2.0 1.5 -50% 1.0 +32% 75 50 Healthcare utilization Events -25% 79 0.5 25 45 Uncontrolled COPD 0.0 T 0 Before 50 100 150 200 50 100 150 200 Uncontrolled Asthma Decrease in medication usage Adherence % 36 36 +58% 57 40 Control Intervention Improvement in adherence 50 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 Improvement in QOL 59 After Reduction in healthcare utilization QoL: Rescue Inhaler use per day # times used Acute care utilization Events per 100 patient years 1.5 1.0 -75% 0.5 0.0 1 180 Improvement in QOL 13 Pre-enrollment Post-enrollment 12 6 5 365 ED + Hosp. ED 2 0 Hosp. Reduction in healthcare utilization ResMed#51Propeller's digital medicine platform drives reduced healthcare utilization ☐ Cleveland Clinic Study Overview: Propeller Cleveland Clinic enrolled people into Propeller as part of their routine clinical care and monitored them for at least one year. Providers monitored drug use and adherence to inhaled controller medications, providing follow-up as needed. Population: COPD patients with ≥1 utilization (Emergency Department ("ED") visit or hospitalization) in prior 12 months N = 39; mean age: 69 years, 51% male, 69% African American, mean FEV11 predicted: 47.2%, mean CAT: 192 Numbe of Hospitalizations and ED visits per person per year LO + M C Results: 12 months prior p = 0.06 4.7 ± 4.1 12 months during monitoring 3.4 ± 2.6 3.4 ± 3.2 2.2 + 2.3 1. FEV1 - Forced Expiratory Volume in 1 second - the volume of air that can be forcibly blown out in the first second after full inspiration. Values between 80% and 120% are considered normal 2. CAT = COPD Assessment Test – an eight-item questionnaire designed to quantify the impact of COPD symptoms on a patient's health status.. Scored between 0-40, <10 Low, 10-20 Medium, 21-30 High, >30 Very high Alshabani K, et al. Electronic inhaler monitoring and healthcare utilization in chronic obstructive pulmonary disease. J Telemed Telecare. 2019 51 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 All-cause COPD Healthcare Utilization ResMed#52Strong track record of M&A Our transformative acquisitions have enabled tuck-in opportunities, creating added capabilities brightree Added Capabilities by ResMed MatrixCare® by ResMed Propeller conduittechnology AllCall Connect - ResMed 2017 Enhanced HMES' custom forms and workflow solutions 2017 Provided live call center services for HMES 2018 Added mobile applications to automate and streamline empower companies to business processes 2018 HEALTHCARE first by ResMed SNAP CitusHealth by ResMed Software solutions to optimize clinical, financial, and administrative processes 2020 Elevated Brightree's ReSupply platform, creating the largest CPAP resupply patient base 2021 Enhanced real-time communication technology, specifically real-time response, to inbound communications Proven ability to integrate and leverage transformative acquisitions and tuck-ins Apacheta CORPORATION Mobile Business Solutions 52 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 Enhanced portfolio ResMed